Navigation Links
Drug Firms Sue British Regulator Over Alzheimer's Drugs

Two drug firms and a charity for people with Alzheimer's disease began a legal challenge Monday against the downgrading of three anti-dementia drugs by British regulators.

In 2001 the National Institute for Health and Clinical Excellence (NICE), which issues guidance on how medicines should be used in Britain, recommended three drugs from US drugs giant Pfizer and Japan's Eisai.

But last year it changed its advice for patients with moderate Alzheimer's after consultation, saying instead that the drugs should only be considered as options.

The drugs -- Aricept, the brand name for donepezil; Exelon, also known as rivastigmine, and Reminyl, or galantamine -- had not proven especially effective for people with mild Alzheimer's, NICE said.

Pfizer and Eisai were due to argue in a four-day hearing at London's High Court that the effectiveness appraisal process for the drugs was unfair and that NICE's decision was both procedurally flawed and irrational.

Lawyer David Pannick, representing Eisai, told judge Linda Dobbs that the change in NICE's guidance meant that 96,600 people per year with mild Alzheimer's would not now receive the drugs.

The Alzheimer's Society, which represents people with dementia, claimed ahead of the hearing that NICE had acknowledged the drugs worked but, at a cost of 2.50 pounds per person per day (3.71 euros, 4.99 dollars), decided they were not cost effective.

"These treatments have benefitted so many families already -- where is the justice in NICE's decision to snatch them away?" Neil Hunt, chief executive of the charity, said.

Andrew Dillon, chief executive of NICE, countered that its recommendations were not unfair and were developed after three years of analysis and discussion with doctors, patients and drug makers.

"For Alzheimer's disease, drugs are only part of the care that needs to be offered," he said.

"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."

Symptoms of Alzheimer's, the commonest form of dementia which affects about 450,000 people in Britain, include mood swings, confusion and withdrawal.


'"/>




Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List
10. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
11. Milk Firms in Philippines Violate Breastfeeding Code: WHO
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology: